PMID- 16680582
OWN - NLM
STAT- MEDLINE
DCOM- 20061019
LR  - 20211020
IS  - 0364-2313 (Print)
IS  - 0364-2313 (Linking)
VI  - 30
IP  - 5
DP  - 2006 May
TI  - Is surgery beneficial for MEN1 patients with small (< or = 2 cm), nonfunctioning 
      pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE.
PG  - 654-62; discussion 663-4
AB  - BACKGROUND: The management of small, nonfunctioning pancreaticoduodenal endocrine 
      tumors (NFPET) in multiple endocrine neoplasia type 1 (MEN1) patients is still 
      controversial. We therefore investigated the effect of surgery on survival and 
      tumor progression in MEN1 patients with NFPET < or = 2 cm by analyzing data from 
      the Groupe des Tumeurs Endocrines (GTE) registry. MATERIALS AND METHODS: Among 
      579 MEN1 patients in the registry, 65 had NFPET < or = 2 cm. Fifteen (23%) 
      underwent pancreatectomy, 9 at least segmental pancreatectomies and 6 biopsies or 
      enucleations (the surgery group), and 50 (77%) were followed conservatively (the 
      no surgery group). Age at MEN1 and NFPET diagnosis was similar in both groups, as 
      was size of the primary tumor. Seven (10.8%) patients had metastases. Five 
      metastases were synchronous, and 2 (one in each group) were metachronous. Tumor 
      size was similar in patients with or without metastasis. RESULTS: There was no 
      perioperative mortality. The average follow-up time after NFPET diagnosis was 6.7 
      years in the surgery group and 3.3 years in the no surgery group. Three (4.6%) 
      patients died during follow-up, 2 due to NFPET and 1 due to thymus tumor. The 2 
      patients who died of NFPET had undergone pancreatic surgery at the time of NFPET 
      diagnosis. The 2 groups did not differ significantly with respect to tumor 
      progression [5/15 (33%) vs 6/38 (16%), P = 0.16]. Overall life expectancy of 
      patients with NFPET < or = 2 cm was not different than that of the 229 MEN1 
      patients in the registry without any pancreaticoduodenal tumor (P = 0.33). 
      CONCLUSIONS: This study suggests that surgery may not be beneficial for MEN1 
      patients with NFPET < or = 2 cm.
FAU - Triponez, Frederic
AU  - Triponez F
AD  - Department of General and Endocrine Surgery, University Hospital, Lille, France. 
      frederic.triponez@hcuge.ch
FAU - Goudet, Pierre
AU  - Goudet P
FAU - Dosseh, David
AU  - Dosseh D
FAU - Cougard, Patrick
AU  - Cougard P
FAU - Bauters, Catherine
AU  - Bauters C
FAU - Murat, Arnaud
AU  - Murat A
FAU - Cadiot, Guillaume
AU  - Cadiot G
FAU - Niccoli-Sire, Patricia
AU  - Niccoli-Sire P
FAU - Calender, Alain
AU  - Calender A
FAU - Proye, Charles A G
AU  - Proye CA
CN  - French Endocrine Tumor Study Group
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - World J Surg
JT  - World journal of surgery
JID - 7704052
SB  - IM
MH  - Adult
MH  - Disease Progression
MH  - Duodenal Neoplasms/mortality/pathology/*surgery
MH  - Humans
MH  - Middle Aged
MH  - *Multiple Endocrine Neoplasia Type 1
MH  - Neoplasm Staging
MH  - Neoplasms, Multiple Primary
MH  - Neoplasms, Second Primary
MH  - Pancreatic Neoplasms/mortality/pathology/*surgery
MH  - Registries
MH  - Retrospective Studies
MH  - Survival Analysis
EDAT- 2006/05/09 09:00
MHDA- 2006/10/20 09:00
CRDT- 2006/05/09 09:00
PHST- 2006/05/09 09:00 [pubmed]
PHST- 2006/10/20 09:00 [medline]
PHST- 2006/05/09 09:00 [entrez]
AID - 10.1007/s00268-005-0354-9 [doi]
PST - ppublish
SO  - World J Surg. 2006 May;30(5):654-62; discussion 663-4. doi: 
      10.1007/s00268-005-0354-9.